STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia

Untreated Chronic Lymphocytic Leukemia Clinical Trial

— STAIR  

Official title:

STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04963946
• Other study ID #: FILOCLL14 - STAIR
• Status: Recruiting
• Phase: Phase 2
• Start date: October 18, 2021
• Est. completion date: August 1, 2028

Study information

• Verified date: June 2024
• Source: French Innovative Leukemia Organisation
• Contact: Marie POINSIGNON-BLANCARD
• Phone: 0467333190
• Email: m.poinsignon-blancard[@]filo-leucemie.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The irreversible Bruton's Tyrosine Kinase (BTK) inhibitor acalabrutinib (ACA) has potent clinical activity as a single agent in patients with treatment naive and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

However, a growing body of concerns is raising regarding the unlimited administration of targeted therapy as BTKi. First, long-term treatments expose the patients to increased risk of specific adverse events (infections, bleeding events or cardiovascular problems). Second, continuous administration might also increase the risk of clonal evolution and therapeutic resistance resulting from genetic alterations such as BTK or PLCG2 mutations. Discontinuation of therapy after a fixed period is expected to prevent these events.

Rapid and deep responses yielded by ACA in elderly patients pave the way of investigating a limited 18-months period schedule. This study aims to investigate the 1-year PFS upon ACA discontinuation and efficacy of restarting ACA upon symptomatic relapse.

Description:

This multicenter, non comparative, randomized phase II trial aims at evaluating the impact of a stopping ACA strategy on PFS of CLL patients >70 years or with coexisting comorbidities.

Patients will receive continuous Acalabrutinib (ACA) at 100 mg bid for 18 months. Dose adaptations will be made according to labels.

In case of first occurrence of grade ≥3 non-hematological toxicity, febrile grade ≥3 neutropenia or grade ≥4 hematological toxicity treatment must be stopped until recovering grade 1 or baseline state.

• 1st and second occurrence : restart at 100 mg twice daily

• 3rd occurrence : restart at 100 mg once daily

• 4th occurrence : discontinue acalabrutinib

At month 19 day 1, patients will be randomized (1:2) in two arms:

• Arm 1 = Control arm (acalabrutinib) continuing acalabrutinib until disease progression or unacceptable toxicity or

• Arm 2 = Experimental arm (watch and monitor) without ACA (see trial design).

Upon progression in the experimental arm, all patients will be re-treated with ACA at the last received dose after central reviewing of treatment criteria.

Upon progression in the control arm, patients will receive next line therapy at the discretion of their physicians and according to iwCLL 2018 criteria.

Patients will be monitored every three months until M31 then every 6 months until M60 or progression for both response and toxicity according to CTCAE v.5.

Minimal/Measurable Residual Disease (MRD) assessment will be done at month 19 day 1 in the peripheral blood.

CT-scan will be performed at baseline, then at month 19 day 1 and every 6 months within the year after randomization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: August 1, 2028
• Est. primary completion date: January 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Age > 70 years or older

• Eastern Cooperative Oncology Group (ECOG) performance status < 2

• Previously untreated CLL or Small Lymphocytic Lymphoma (SLL)

• CLL or SLL requiring treatment according to the iwCLL 2018 criteria2

• Total Cumulative Illness Rating Scale (CIRS) score > 6 or 30 < CrCl < 69 mL/min

• Both patients with or without TP53 disruption 17p deletion and/or TP53 mutations) can be included

• Patients can be included whatever their IGHV mutational status

• Patients with therapy-controlled cardiovascular comorbidities and/or anticoagulation (novel oral anticoagulant alone, aspirin alone, heparin alone) can be included (patients treated by vitamin K antagonist or dual anti-platelet therapy cannot be included)

• Life expectancy > 6 months

• Adequate hematology values: absolute neutrophil count = 0.75 x 109/L, platelet count = 50 x 109/L.

• Adequate liver function as indicated by a total bilirubin <1.5, aspartate transaminase and alanine transaminase =3 the institutional upper limits of normal values, unless directly attributable to CLL

• Signed (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including specify biology analysis, and are willing to participate in the study.

Exclusion Criteria:

• Known HIV seropositivity

• Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

• Uncontrolled and/or active systemic infection (viral, bacterial or fungal)

• Known history of human immunodeficiency virus, serologic status reflecting active hepatitis B virus or hepatitis C virus infection, any uncontrolled active systemic infection along with subjects who are on ongoing anti-infective treatment and subjects who have received vaccination with a live attenuated vaccine within 4 weeks before the first dose of study treatment

1. Subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antibody (anti-HBs) negative will need to have a negative hepatitis B virus Polymerase Chain Reaction (PCR) result before enrollment. Those who are hepatitis B surface antigen (HBsAg) positive or hepatitis B virus PCR positive will be excluded.

2. Subjects who are hepatitis C virus antibody positive will need to have a negative hepatitis C virus PCR result before enrollment. Those who are hepatitis C virus PCR positive will be excluded

• Active and uncontrolled autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA) (isolated positive Direct Antiglobulin Testing (DAT) is not an exclusion criteria) and idiopathic thrombocytopenic purpura (ITP).

• Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura.

• Patients treated by vitamin K antagonist or dual anti-platelet therapy

• History of bleeding diathesis (e.g. hemophilia or von Willebrand disease)

• History of confirmed progressive multifocal leukoencephalopathy (PML).

• Concurrent severe diseases which exclude the administration of therapy :

• heart insufficiency New York Heart Association (NYHA) grade III/IV, Left Ventricular Ejection Fraction (LEVF) < 50% and or Recirculation Fraction (RF) < 30%, myocardial infarction within the past 6 months prior to study

• Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional (Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study)

• severe chronic obstructive lung disease with hypoxemia

• history of stroke or intra-cranial hemorrhage within the last 6 months

• severe diabetes mellitus

• uncontrolled hypertension

• impaired renal function with creatinine clearance < 30 ml/min according the formula of Cockcroft and Gault

• Patient who requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton-pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment in this study.

• Disease significantly affecting gastrointestinal function (malabsorption syndrome, stomach or small bowel resection)

• Evidence for Richter syndrome

• Treatment with any of the following within 7 days prior to the first dose of study drug: steroid therapy for anti-neoplastic intent.

• A significant history of renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, or hepatic disease that, in the opinion of the investigator, would adversely affect the patient's participation in this study or interpretation of study outcomes

• Major surgery within 30 days prior to the first dose of study treatment.

• History of prior other malignancy that could affect compliance with the protocol or interpretation of results, with the exception of the following:

• curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study.

• other cancers not specified above that have been curatively treated by surgery and/or radiation therapy from which patient is disease-free for = 5 years without further treatment

• Adult under law-control

• Fertile male patients who cannot or do not wish to use an effective method of contraception, during and for 12 months after the final treatment used for the purposes of the study

• No affiliation to social security

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Untreated Chronic Lymphocytic Leukemia

Intervention

Drug:
• Stop ACA
discontinuation of acalabrutinib after 18 months in treatment-naïve CLL patients
• ACA Continuation
continuation of acalabrutinib at the same dose

Locations

Country	Name	City	State
France	Chu Angers	Angers
France	ARGENTEUIL - Centre hospitalier Victor Dupouy	Argenteuil
France	Ch Avignon	Avignon
France	Ch Cote Basque	Bayonne
France	BOBIGNY - Hôpital Avicenne	Bobigny
France	Hôpital Privé Sévigné	Cesson-Sévigné
France	CHU Estaing - Hématologie Clinique Adulte	Clermont-Ferrand
France	Corbeil-Essonnes -	Corbeil-Essonnes
France	CHU Grenoble - Hématologie	Grenoble
France	Centre Hospitalier du Mans	Le Mans
France	Hôpital Saint Vincent de Paul	Lille
France	Centre Léon Bérard - Hématologie	Lyon
France	Institut Paoli-Calmettes - Hématologie Clinique	Marseille
France	Centre Hospitalier Regional Metz Thionville	Metz
France	Hôpital Saint-Eloi - Hématologie Clinique	Montpellier
France	Hopital E.Muller	Mulhouse
France	CHR ORLEANS - Hématologie	Orléans
France	Hopital Pitie Salpetriere Service Hematologie Clinique - Pavillon de L'Enfant Et Adolescent	Paris
France	CENTRE HOSPITALIER SAINTJEAN - Hématologie Clinique	Perpignan
France	Bordeaux Pessac	Pessac
France	Centre Hospitalier Lyon Sud	Pierre-Bénite
France	Hôpital de la Milétrie - Hématologie et Thérapie Cellulaire	Poitiers
France	CERGY-PONTOISE - Centre Hospitalier René Dubos	Pontoise
France	Chu Reims	Reims
France	CHU Pontchaillou - Hématologie Clinique BMT-HC	Rennes
France	Centre Henri Becquerel - Service Hématologie Clinique	Rouen
France	Institut de Cancérologie Lucien Neuwirth	Saint-Priest-en-Jarez
France	IUCT ONCOPOLE - Hématologie	Toulouse
France	Hôpital Bretonneau - Hématologie et Thérapie Cellulaire	Tours
France	CHU Nancy Brabois	Vandœuvre-lès-Nancy
France	Vannes - Chba	Vannes
France	VERSAILLES - Hôpital André Mignot	Versailles

Sponsors (1)

Lead Sponsor	Collaborator
French Innovative Leukemia Organisation

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS) at one year after acalabrutinib interruption	Time from randomization (M19 : discontinuation of acalabrutinib after of 18 months treatment) to progression (needing therapy or not) or death from any cause	until 12 months after acalabrutinib interruption